CD8A and Patent ductus arteriosus: Consistent with evidence suggesting that increased IL-33 levels promote antitumor T cell responses, PDA tumor growth was profoundly inhibited in the rIL-33 group compared with control conditions (Figure 9G) with concomitant and robust increases in CD8+ T cell infiltration (Figure 9H).